C. Aspord

发表

Dendritic cell subsets in health and disease

H. Ueno, E. Klechevsky, R. Morita, 2007, Immunological reviews.

Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection.

C. Aspord, J. Plumas, J. Martinet, 2012, Gastroenterology.

A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy.

C. Aspord, C. Trocmé, B. Polack, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Early events in islets and pancreatic lymph nodes in autoimmune diabetes.

C. Aspord, S. Rome, C. Thivolet, 2004, Journal of autoimmunity.

T‐cell receptor diversity as a prognostic biomarker in melanoma patients

C. Aspord, F. de Fraipont, J. Plumas, 2020, Pigment cell & melanoma research.

Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model.

C. Aspord, Jean Martínez, D. Boturyn, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Diversification of circulating and tumor‐infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1−)‐pDC subset negatively correlated with clinical outcomes in melanoma patients

C. Aspord, F. de Fraipont, L. Chaperot, 2022, Clinical & translational immunology.

Hepatitis B virus exploits C‐type lectin receptors to hijack cDC1s, cDC2s and pDCs

C. Aspord, T. Decaens, D. Durantel, 2020, Clinical & translational immunology.

Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection

C. Aspord, T. Decaens, D. Durantel, 2019, Front. Immunol..

An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial

C. Aspord, P. Coulie, B. Dréno, 2020, Oncoimmunology.

Nanoprobes to Monitor Cell Processes in the Pancreas

P. Perriat, O. Tillement, C. Aspord, 2012 .

T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging.

C. Aspord, F. Gazeau, M. Janier, 2005, Radiology.

Exploration of the Lysis Mechanisms of Leukaemic Blasts by Chimaeric T-Cells

C. Aspord, H. Vié, J. Plumas, 2010, Journal of biomedicine & biotechnology.

[GENiusVac, a novel antitumor vaccine strategy based on allogeneic plasmacytoid dendritic cells].

C. Aspord, M. Richard, J. Plumas, 2011, La Revue de medecine interne.

A Novel Cancer Vaccine Strategy Based on HLA-A*0201 Matched Allogeneic Plasmacytoid Dendritic Cells

C. Aspord, M. Richard, J. Plumas, 2010, PloS one.

Nasal administration of CTB‐insulin induces active tolerance against autoimmune diabetes in non‐obese diabetic (NOD) mice

C. Aspord, C. Thivolet, 2002, Clinical and experimental immunology.

Melanoma hijacks plasmacytoid dendritic cells to promote its own progression

C. Aspord, J. Plumas, M. Leccia, 2014, Oncoimmunology.

Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection

C. Aspord, F. Zoulim, M. Richard, 2012, Hepatology.

X-Chromosome Complement and Estrogen Receptor Signaling Independently Contribute to the Enhanced TLR7-Mediated IFN-α Production of Plasmacytoid Dendritic Cells from Women

C. Aspord, J. Plumas, J. Guéry, 2014, The Journal of Immunology.

This information is current as from Women Production of Plasmacytoid Dendritic Cells α to the Enhanced TLR 7-Mediated IFN-ContributeReceptor Signaling Independently X-Chromosome Complement and Estrogen

C. Aspord, J. Plumas, J. Guéry, 2014 .

The avidity of tumor‐specific T cells amplified by a plasmacytoid dendritic cell‐based assay can predict the clinical evolution of melanoma patients

C. Aspord, J. Plumas, L. Chaperot, 2018, Pigment cell & melanoma research.

Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th2 and Regulatory Immunity through OX40L and ICOSL

C. Aspord, J. Plumas, M. Leccia, 2013, Cancer Immunology Research.

pDCs efficiently process synthetic long peptides to induce functional virus‐ and tumour‐specific T‐cell responses

C. Aspord, J. Plumas, C. Leloup, 2014, European journal of immunology.

alpha4 integrins and L-selectin differently orchestrate T-cell activity during diabetes prevention following oral administration of CTB-insulin.

C. Aspord, C. Czerkinsky, C. Thivolet, 2002, Journal of autoimmunity.

Reply to Comment on “Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” Cancers 2019, 11, 1554

C. Aspord, T. Decaens, Z. Macek Jílková, 2020, Cancers.

Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses

C. Aspord, F. Mami-Chouaib, F. Soncin, 2017, Oncoimmunology.

Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection

C. Aspord, F. Zoulim, J. Plumas, 2016, PloS one.

Adenovirus-Inspired Virus-like-Particles Displaying Melanoma Tumor Antigen Specifically Target Human DC Subsets and Trigger Antigen-Specific Immune Responses

C. Aspord, J. Kleman, F. Fieschi, 2022, Biomedicines.

Circulating IL-13 Is Associated with De Novo Development of HCC in HCV-Infected Patients Responding to Direct-Acting Antivirals

C. Aspord, T. Decaens, P. Marche, 2020, Cancers.

Hideki Ueno Eynav Klechevsky Rimpei Morita Caroline Aspord Tinghua Cao Toshimichi Matsui Tiziana Di Pucchio John Connolly

R. Morita, C. Aspord, J. Fay, 2007 .

Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer.

C. Aspord, M. Richard, R. Gressin, 2010, European journal of dermatology : EJD.

Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion

C. Aspord, F. Zoulim, J. Plumas, 2016, PloS one.

Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor development

C. Aspord, J. Banchereau, A. Palucka, 2007, The Journal of experimental medicine.

Humanized mice for the development and testing of human vaccines

C. Aspord, J. Banchereau, A. Palucka, 2007, Expert opinion on drug discovery.

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges

C. Aspord, T. Decaens, Z. Macek Jílková, 2019, Cancers.

BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients

C. Aspord, F. de Fraipont, L. Chaperot, 2020, Clinical & translational immunology.

Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells

C. Aspord, B. Quesnel, T. Idziorek, 2016, Scientific Reports.

Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.

C. Aspord, J. Plumas, M. Leccia, 2014, The Journal of investigative dermatology.

Stimulation of the immune system by a tumor antigen-bearing adenovirus-inspired VLP allows control of melanoma growth

C. Aspord, P. Fender, D. Laurin, 2022, Molecular therapy. Methods & clinical development.

The features of circulating and tumor-infiltrating γδ T cells in melanoma patients display critical perturbations with prognostic impact on clinical outcome

C. Aspord, F. de Fraipont, J. Plumas, 2019, Oncoimmunology.

HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients.

C. Aspord, J. Plumas, L. Chaperot, 2012, The Journal of investigative dermatology.

DNA repair-based classification of melanoma cell lines reveals an effect of mutations in BRAF and NRAS driver genes on DNA repair capacity

C. Aspord, F. de Fraipont, S. Sauvaigo, 2020, bioRxiv.

Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation

C. Aspord, J. Banchereau, A. Palucka, 2011, The Journal of experimental medicine.

Unique CLR expression patterns on circulating and tumor-infiltrating DC subsets correlated with clinical outcome in melanoma patients

C. Aspord, F. de Fraipont, L. Landemarre, 2022, Frontiers in Immunology.

The melanoma tumor glyco-code impacts human dendritic cells’ functionality and dictates clinical outcomes

C. Aspord, F. de Fraipont, F. Fieschi, 2023, Frontiers in Immunology.

Dysfunctional BTN3A together with deregulated immune checkpoints and type I/II IFN dictate defective interplay between pDCs and γδ T cells in melanoma patients, which impacts clinical outcomes

C. Aspord, F. de Fraipont, L. Chaperot, 2021, Clinical & translational immunology.

Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th 2 and Regulatory Immunity through OX 40 L and ICOSL

C. Aspord, J. Plumas, M. Leccia, 2013 .

Immunotherapy via dendritic cells.

C. Aspord, J. Fay, V. Pascual, 2005, Advances in experimental medicine and biology.

A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients

C. Aspord, E. Brambilla, C. Brambilla, 2023, International journal of molecular sciences.

Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment

C. Aspord, T. Decaens, C. Sengel, 2019, Clinical and translational gastroenterology.

Induction of Antiviral Cytotoxic T Cells by Plasmacytoid Dendritic Cells for Adoptive Immunotherapy of Posttransplant Diseases

C. Aspord, H. Vié, M. Richard, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor.

C. Aspord, J. Di Domizio, J. Plumas, 2010, The Journal of investigative dermatology.

Dendritic Cell Subsets in Melanoma: Pathophysiology, Clinical Prognosis and Therapeutic Exploitation

C. Aspord, P. Saas, Eleonora Sosa Cuevas, 2023, Cancers.

Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation

C. Aspord, P. Marche, Z. Macek Jílková, 2023, Frontiers in Immunology.

Impaired Antitumor Immune Response in MYCN-amplified Neuroblastoma Is Associated with Lack of CCL2 Secretion and Poor Dendritic Cell Recruitment

C. Aspord, H. Sartelet, L. Chaperot, 2022, Cancer research communications.

Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints

C. Aspord, L. Chaperot, J. Charles, 2020, Frontiers in Immunology.

Paramagnetic nanoparticles to track and quantify in vivo immune human therapeutic cells.

P. Perriat, O. Tillement, C. Aspord, 2013, Nanoscale.

Upregulation of Adhesion Molecules on Leukemia Targets Improves the Efficacy of Cytotoxic T Cells Transduced With Chimeric Anti-CD19 Receptor

C. Aspord, H. Vié, J. Plumas, 2013, Journal of immunotherapy.

Identification of a predictive metabolic signature of response to immune checkpoint inhibitors in non-small cell lung cancer: METABO-ICI clinical study protocol.

C. Aspord, A. Le Gouellec, D. Moro-Sibilot, 2021, Respiratory medicine and research.

Breast tumor environment inhibits human plasmacytoid dendritic cell functions

J. Blay, C. Aspord, J. Banchereau, 2008 .

Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model.

C. Aspord, Jean Martínez, D. Boturyn, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Humanized mice for the development and testing of human vaccines

C. Aspord, J. Banchereau, A. Palucka, 2007, Expert opinion on drug discovery.

Glycans in melanoma: Drivers of tumour progression but sweet targets to exploit for immunotherapy.

C. Aspord, Eleonora Sosa Cuevas, Philippe Saas, 2024, Immunology.

Harnessing Immune Cell Metabolism to Modulate Alloresponse in Transplantation

C. Aspord, P. Cravedi, Johan Noble, 2024, Transplant international : official journal of the European Society for Organ Transplantation.